Core Viewpoint - China Resources Sanjiu (SZ 000999) held its 12th board meeting for 2025 on October 23, 2025, where the agenda included the review of the Q3 2025 report [1] Company Summary - For the first half of 2025, the revenue composition of China Resources Sanjiu was as follows: pharmaceutical industry accounted for 86.64%, retail industry for 11.75%, and packaging and printing industry for 1.6% [1] - As of the report date, the market capitalization of China Resources Sanjiu was 48.7 billion yuan [1] Industry Summary - In 2023, Chinese innovative drugs have generated overseas licensing sales of 80 billion USD [1] - The secondary market for biopharmaceuticals is currently active, while the primary market is experiencing a cooling in fundraising [1]
华润三九:10月23日召开董事会会议